LimmaTech Biologics

Switzerland
Schlieren, Zurich, Switzerland, 8952

Company profile

LimmaTech Biologics company profile

LimmaTech Biologics is a clinical-stage biotech company that develops vaccines to prevent life-threatening diseases. The company uses proprietary self-adjuvanting and multi-antigen vaccine platforms to address microbial infections that are becoming resistant to treatments. Its research and development efforts aim to create vaccines tailored to specific pathogens. LimmaTech Biologics works on expanding its pipeline to provide solutions for infectious diseases with limited treatment options.

Business identity

Contact email
[email protected]
Phone number
+41 44 733 8585
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$0-$1M
Founded
2015-01-01, Year

Headquarters

Postal code
8952
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$39.5M
Last funding
Grant / $6.5M / 2025-02-17
Last equity funding
Series A / $3M
Investors
5
Lead investors
4
Founders
3
Articles
35

Founders and investors

Founders

Michael KowarikPaul WolfromVeronica Gambillara Fonck

Lead investors

Adjuvant CapitalAXA Investment ManagersCARB-XRepair Impact Fund

Investors

Adjuvant CapitalAXA Investment ManagersCARB-XRepair Impact FundTenmile